Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer.

ABSTRACT:

Purpose

Advanced-stage endometrial cancers have limited treatment options and poor prognosis, highlighting the need to understand genetic drivers of therapeutic vulnerabilities and/or prognostic predictors. We examined whether prospective molecular characterization of recurrent and metastatic disease can reveal grade and histology-specific differences, facilitating enrollment onto clinical trials.

Experimental design

We integrated prospective clinical sequencing and IHC data with detailed clinical and treatment histories for 197 tumors, profiled by MSK-IMPACT from 189 patients treated at Memorial Sloan Kettering Cancer Center.

Results

Patients had advanced disease and high-grade histologies, with poor progression-free survival on first-line therapy (PFS₁).

SUBMITTER: Soumerai TE 

PROVIDER: S-EPMC6279519 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature